Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia

Blood

Volumn 106, Issue 13, 2005, Pages 4303-4307

  Faderl, Stefan ^b   Do, Kim Anh ^b   Johnson, Marcella M ^b   Keating, Michael ^b   O'Brien, Susan ^b   Jilani, Iman ^b   Ferrajoli, Alessandra ^b   Ravandi Kashani, Farhad ^b   Aguilar, Christine ^b   Dey, Amanda ^b   Thomas, Deborah A ^b   Giles, Francis J ^b   Kantarjian, Hagop M ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; RITUXIMAB; THROMBOPOIETIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

EID: 28844434241     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1010     Document Type: Article

References (41)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med. 1995;1:27-31.
3. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000;111:43-51.
4. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
5. Montesano R, Vassalli JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A. 1986;83:7297-7301.
6. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115-165.
7. Fuhrmann-Benzkein E, Ma MN, Rubbia-Brandt L, et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer. 2000;85:40-45.
8. Pantschenko AG, Pushkar I, Anderson KH, et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003;23:269-284.
9. Hatzi E, Murphy C, Zoephel A, et al. N-myc oncogene overexpression down-regulates IL-6: evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene. 2002;221:3552-3561.
10. Lin Y, Huang R, Chen L, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer. 2004;109:507-515.
11. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A. 2003;100:12718-12723.
12. Brizzi MF, Battaglia E, Montrucchio G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res. 1999;84:785-796.
13. Thomas DA, Giles FJ, Cortes J. Antiangiogenesis therapy in leukemia. Acta Heamatol. 2001;106:190-207.
14. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
15. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
16. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
17. Yetgin S, Yenicescu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:83-88.
18. Pulè MA, Gullmann C, Dennis D, et al. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br J Haematol. 2002;118:991-998.
19. Kantarjian H, Thomas D, O'Brien S, et al. Longterm follow up results of hyperfractionated cyclosphosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788-2801.
20. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
21. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17:2461-2470.
22. Therneau T, Grambsch P, Fleming T. Martingalebased residuals for survival models. Biometrika. 1990;77:147-160.
23. Venables WN, Ripley BD. Modern applied statistics with S-Plus. In: Eddy W, Hardle W, Scheatter S, and Tierney L, eds. Tree-Based Methods. New York, NY: Springer-Verlag; 1994:329-347.
24. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics. 1992;48:411-425.
25. Clark LA, Pregibon D. Tree-based models. In: Chambers JM, Hastie TJ, eds. Statistical Models in S-Plus. Pacific Grove, CA: Wadsworth & Brooks/Cole; 1992:377-499.
26. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
27. SAS/STAT User's Guide. Version 8. Cary, NC: SAS Institute, 1999.
28. S-PLUS 2000, Professional Release 3. Seattle, WA: Data Analysis Products Division/MathSoft, 1988-2000.
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
30. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularization to metastasis of nonsmall-cell lung cancer. Lancet. 1992;340:144-146.
31. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
32. Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer. 1997;79:220-225.
33. Aref S, Mabed M, Sakrana M, et al. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics. Hematology. 2002;7:273-279.
34. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923-1930.
35. Koomagi R, Zintl F, Sauerbrey, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res. 2001;7:3381-3384.
36. Schneider P, Vasse M, Legrand E, et al. Have urinary levels of the angiogenic factors, basic fi-broblast growth factor and vascular endothelial growth factor, a prognostic value in childhood acute lymphoblastic leukaemia? Br J Haematol [correspondence]. 2003;122:163-164.
37. Bikfalvi A, Han ZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia. 1994;8:523-529.
38. Bertolini F, Mancusco P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000;28:993-1000.
39. Hu Q, Dey AL, Yang Y, et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer. 2004;100:1884-1891.
40. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implications in therapy with anti-CD52 antibodies. Cancer. 2004;101:999-1008.
41. Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595-604.